Neovascularization is a common feature of many human cancers, but relatively few molecular defects have been demonstrated in genes regulating angiogenesis. Decreased expression of Thrombospondin-1 (THBS1), a P53 and Rb regulated angiogenesis inhibitor, has been observed in some human tumors, including glioblastoma multiforme (GBM). To study whether methylationassociated inactivation is involved in down-regulating THBS1 expression in cancer, we analysed the methylation status of THBS1 in several cell lines and primary tumors. Three cell lines (RKO, CEM and RAJI) were completely methylated at several CpG sites within the THBS1 5' CpG island, and had no detectable expression by RT ± PCR. THBS1 expression was readily reactivated using the methylation-inhibitor 5-deoxy-azacytidine in all three lines. Furthermore, THBS1 methylation was present in 33% (14/42) of primary GBMs. Thus, de novo methylation may serve as a potential way to inactivate THBS1 expression in human neoplasms.
Introduction
THBS1 is a matrix-bound adhesive glycoprotein which is synthesized and produced in a variety of human tissues (Bornstein, 1992) , including platelets, endothelial cells, ®broblasts, smooth muscle cells, monocytes, granular pneumocytes, neurons and glial cells. Recent studies have indicated that its expression can be positively regulated by P53 (Dameron et al., 1994) , RB (Salnikow et al., 1994) , nm-23 and one or more unknown genes on chromosome 10q (Hsu et al., 1996) . Several lines of evidence suggest that THBS1 is an inhibitor of angiogenesis: (i) THBS1 is present in quiescent vessels and decreased or absent in actively forming endothelial sprouts or cultured endothelial cells forming tubules (Can®eld and Schor, 1995; DiPietro et al., 1994) ; (ii) THBS1 expression is shut o in rapidly growing endothelial cells from mouse hemangiomas induced by the polyoma virus middle t antigen (Sheibani and Frazier, 1995) ; (iii) wild type P53 inhibits angiogenesis by stimulating the production of THBS1 in ®broblast cells (Dameron et al., 1994) ; (iv) THBS1 inhibits endothelial cell adhesion, growth and motility in response to angiogenic stimuli (Panetti et al., 1997) , and it also has the ability to induce apoptosis in endothelial cells (Guo et al., 1997) ; and (v) downregulation of THBS1 expression in endothelial cells enhances in vitro angiogenesis (DiPietro et al., 1994) . Thus, THBS1 appears to be a potent anti-angiogenic factor.
Several studies have implicated alterations in THBS1 expression in the neovascularization observed in human cancers (Roberts, 1996) : Decreased expression of THBS1 has been reported in multiple primary tumors (Grossfeld et al., 1997; Zabrenetzky et al., 1994; Clezardin et al., 1993) and cells transformed in vitro by c-jun (Mettouchi et al., 1994) , Nickel (Salnikow et al., 1994) , v-src (Slack and Bornstein, 1994) , the polyoma virus middle-t antigen (Sheibani and Frazier, 1995) , and v-myc (Tikhonenko et al., 1996) . Reexpression of THBS1 reduced tumor growth, angiogenesis and metastasis in a hemangioma cell line (Sheibani and Frazier, 1995) and a breast cancer cell line (WeinstatSaslow et al., 1994) . In addition, several tumorsuppressor genes appear to regulate angiogenesis through THBS1 expression (Hsu et al., 1996; Dameron et al., 1994; Good et al., 1990) . However, no mutations, translocations or deletions involving THBS1 have been reported to date.
Because methylation of promoter-associated CpG islands has been implicated in the transcriptional inactivation of selected genes in cancer Issa et al., 1997; Jones, 1996) , we speculated that hypermethylation of the THBS1 gene may be a potential way for tumor cells to escape the antiangiogenic eects of this molecule. Our data now con®rm that methylation of THBS1 promoter, and associated transcriptional silencing, can be found in a variety of human tumors, including GBMs.
Results

THBS1 methylation in tumor cell lines
The THBS1 promoter is contained in a typical CpG island which starts 1.3 kb upstream of exon 1 and ends in intron 1. This area has a CpG frequency of 8.6%, a CpG:GpC ratio of 0.8, and contains several methylation-sensitive restriction enzyme sites including ®ve EagI sites, three SacII sites and one NotI site ( Figure  1) .
We initially analysed the methylation status of THBS1 in normal tissues and 27 neoplastic cell lines using Southern blot analysis (Figure 2 ). The cell lines analysed included colorectal cancer (RKO, Caco2, LoVo, DLD1, HT29, SW48, SW480, HCT116, Colo205, SW837), prostate cancer (LnCAP, TSU-PR1, DU145), lung cancer (OH3, HUT64, H209), gliomas (U87, U373), hematopoietic malignancies (RAJI, Jurkat, ML1, K562, MOLT3, CEM, HL60) and others (HepG2, HT1080). Using either the 5' probe (examples in Figure 2a ), the 3' probe (examples in Figure 2b ) or bisul®te-PCR analysis (Figure 2c ), THBS1 was completely unmethylated in all normal tissues examined (colon, brain, ®broblasts, bone marrow, peripheral blood lymphocytes, lung, kidney, breast, aorta, stomach, liver, lymph node). By contrast, the NotI site and/or the EagI sites in the THBS1 CpG island were completely methylated in four cell lines (RKO, SW48, CEM and RAJI) and partially methylated in ®ve cell lines (LNCaP, Jurkat, K562, MOLT3, HL60). When tested, identical results were obtained using either NotI, EagI or SacII as the methylation-sensitive enzyme. In addition, the results were the same whether we used the 3' or the 5' probe (compare RKO in Figure 2a and b).
To con®rm that this hypermethylation also involves CpG sites within the transcription start area of the gene, we used a slight modi®cation of several described bisul®te-PCR approaches (Xiong and Laird, 1997; Sadri and Hornsby, 1996; Herman et al., 1996) . PCR primers surrounding the transcription start site were designed based on the bisul®te-converted sequence, and the primers did not include CpG sites in order to equally amplify methylated and unmethylated DNA. The PCR fragment obtained from ampli®cation of bisul®te treated DNA was then restricted with either BstUI, TaqI or BsmI, and analysed by agarose gel electrophoresis. In this analysis, the restriction enzyme site is only present if DNA was methylated prior to bisul®te conversion. Applying this method to normal tissues (colon and brain) and ten neoplastic cell lines, we obtained results identical to the Southern blot data outlined above i.e. no methylation in normal tissues, high levels of methylation in RKO, SW48, CEM and RAJI, and no methylation in Caco2, LoVo, DLD-1, HT29, SW480 and HCT116 (examples in Figure 2c ). In RKO, SW48, CEM and RAJI, methylation appears to be 100% by NotI site (Southern blot) analysis, but slightly less than 100% by bisul®te/PCR analysis, ranging from 90 ± 98%. This is probably due to the fact that Southern blot/NotI site analysis is more sensitive because it detects methylation of any one of the two CpG sites in its recognition sequence. By contrast, PCR/BstUI methylation requires that two adjacent CpG sites are both simultaneously methylated to appear as an abnormal band. In fact, CpG island methylation in cancer is known not to always involve every single CpG site on each allele (Stirzaker et al., 1997) .
THBS1 expression correlates with its methylation status
Since hypermethylation of promoter CpG islands is usually associated with inactivation of gene transcription (Meehan et al., 1992) , we next analysed the relationship between THBS1 methylation and expression status in human tissues. Using RT ± PCR ( Figure  3a ), we found that normal colon, normal bone marrow, normal aortic endothelial cells and all ten unmethylated cell lines examined (U87, U373, Caco2, SW837, LOVO, HT29, HCT116, DLD1, Tsu-Pr1 and ML1) had abundant expression of THBS1 RNA. By contrast, all four cell lines with complete THBS1 methylation examined had either no detectable expression (RKO, CEM and RAJI) or trace levels of expression (SW48) using RT ± PCR. The partially methylated cell line LNCaP expressed THBS1, possibly through transcription from unmethylated alleles. Treatment of RKO, CEM and RAJI with the methylation inhibitor 5-deoxy-azacytidine resulted in re-expression of THBS1 ( Figure 3b , left panel) and demethylation of its promoter (ranging from 18 ± 45%, Figure 3c , right panel) in all three cell lines.
THBS1 methylation in GBM
GBMs exhibit high levels of neovascularization (Wesseling et al., 1997; Furnari et al., 1995) , and alterations in THBS1 expression have been implicated in this process (Hsu et al., 1996) . To determine the potential role of THBS1 methylation in GBM, DNA from four normal brain samples and 42 primary GBMs were analysed by either Southern blot analysis (ten samples), bisul®te/PCR (seven samples), or both (29 samples) as described above. No methylation was observed in the four normal brain samples (Figure 2a and data not shown). By contrast, 14/42 (33%) GBMs Figure 1 Map of the promoter region of the THBS1 gene. Top: CpG density of the area is represented by vertical lines corresponding to each CpG site. The high density of these sites around the ®rst exon indicates the presence of a CpG island. Middle: Restriction map of the area, along with the location of the ®rst 3 exons of the THBS1 gene (lightly shaded boxes labeled 1 ± 3 for exons 1 ± 3). The transcription start site is indicated by an arrow. E1, EcoRI; H, HindIII; E, EagI; S, SacII and N, NotI. Bottom: Locations of the two probes used in this study (THBS1-12 and THBS1-34), and of the primers (arrowhead) used for the bisul®te-PCR methylation analysis
Thrombospondin-1 promotor methylation in cancer Q Li et al displayed signi®cant methylation of the THBS1 CpG island (examples in Figure 4 ). Southern blot analysis and bisul®te/PCR gave identical results in all 29 samples studied by both methods simultaneously. THBS1 methylation did not correlate with age, gender or overall survival in this small series. In a previous study (Li et al., 1998) , we have described frequent and concordant ER and N33 methylation in GBMs. ER and N33 methylation data was available for 34 cases. There was no correlation between THBS1 methylation and either ER or N33 methylation in these samples.
Discussion
In the present study, we have shown that a CpG island that contains the THBS1 promoter is methylated in several neoplastic cell lines, and in a subset of GBM primary tumors. This methylation is associated with loss of gene expression in cell lines, and demethylation using a methyltransferase inhibitor can partially restore expression at the mRNA level. While we have not studied directly the expression of THBS1 in GBMs, there is extensive data correlating promoter methylation with loss of gene expression in primary cancers Jones, 1996) , and the degree of methylation observed would be expected to silence gene expression in vivo as well as in vitro.
Several studies have indicated that THBS1 may have tumor suppressive properties in vivo, presumably through inhibition of neovascularization (Roberts, 1996) . Down-regulation of THBS1 expression, however, had been attributed to loss of transcriptional activation by P53, Rb or one or more putative tumor suppressor gene on chromosome 10, and no mutations have been described in this gene to date. Interestingly, down-regulation of THBS1 has been described following cell transformation using Nickel (Salnikow et al., 1994) . Other studies from the same group have suggested that Nickel-induced transformation may involve epigenetic mechanisms (Klein et al., 1991) , including chromatin condensation and DNA methylation (Lee et al., 1995) , suggesting that THBS1 expression may have been lost by aberrant methylation in that system. More recent data demonstrated that inactivation of THBS1 in this system is not associated with aberrant methylation, and may have been caused by Nickel-related induction of ATF1, a negative regulator of THBS1 transcription (Salnikow et al., 1997) . Our data now suggests that, in some tumors, loss of THBS1 expression may be directly related to inactivation of its promoter in association with CpG island methylation. Thus, it is quite possible that inactivation of THBS1 involves multiple mechanisms in GBM, and it would be interesting to determine whether THBS1 methylation correlates with P53 mutations (or lack thereof) or chromosome 10 allelic status in GBM. In addition, it would be interesting to compare THBS1 methylation with the expression of other angiogenic factors in GBM such as VEGF (Cheng et al., 1996; Plate et al., 1992) and/or a P53 regulated angiogenesis inhibitor that appears to be distinct from THBS1 (Van Meir et al., 1994) .
The cause of THBS1 methylation in cancers remains to be de®ned. We have previously shown THBS1 Figure 1) . The 0.9 kb band does not contain a NotI site and does not change in size if the promoter is methylated. The 3.2 kb band (indicated by an arrow) cuts down to 1.3 kb if the NotI site is unmethylated. Note that normal colon and brain are unmethylated as are cell lines Caco2, ML1, Tsupr1, U87 and U373. RKO, CEM and RAJI are completely methylated, while LnCAP is partially methylated at this NotI site. (b) Composite Southern blot of representative gels demonstrating hypermethylation of the NotI site in colorectal cancer. DNA was digested with EcoRI and NotI and probed with THBS1-12 (see Figure 1) . The 3.5 kb band (indicated by an arrow) cuts down to 2.0 kb if the NotI site is unmethylated. Note that two out of ®ve colorectal cancer cell lines with mismatch repair de®ciency (MI+) are methylated, while none of the ®ve mismatch repair pro®cient (MI7) cell lines were methylated. The faint band at around 3.7 kb is due to a DNA repeat detected by the 3' probe (but not by the 5' probe). (c) Bisul®te-PCR analysis of methylation around the THBS1 transcription start site. Bisul®te-treated DNA was ampli®ed with THBS1-speci®c primers, yielding a 187 bp fragment. This PCR product was then digested with either BstUI, TaqI or BsmI, all of which contain CG sites in their recognition sequence (left panel). Only methylated DNA sequences will be cut in this analysis, since unmethylated CG sites are converted to TG by bisul®te treatment. Note that the RKO cell line is methylated at all sites tested (left panel). Shown in the right panel, are nine dierent cell lines subjected to bisul®te-PCR, followed by digestion of the ampli®ed product with BstUI, and agarose gel electrophoresis. Note that there is an excellent correlation between Southern blot and bisul®te-PCR analysis, as RKO, SW48, CEM and RAJI are hypermethylated while Caco2, DLD1, HCT116, HT29 and LOVO are unmethylated by both PCR (right panel) and Southern blot analysis (a and b)
Thrombospondin-1 promotor methylation in cancer Q Li et al Figure 3 Expression of THBS1 in cancer cell lines correlates with its promoter methylation status. (a) THBS1 expression was determined by RT ± PCR using primers that yield a fragment of 550 bp. Integrity of RNA was veri®ed by RT ± PCR using primers speci®c for the GAPDH gene (which yield a 306 bp fragment). In some lanes, a non-speci®c PCR product of around 530 bp can also be seen. All reactions were controlled using RT-samples where the RT enzyme was omitted (not shown). Note that normal colon and normal bone marrow express THBS1, as do most of the cell lines, except RKO, CEM and RAJI, which are completely methylated at the THBS1 promoter. SW48, which is also completely methylated, expresses very low amounts of message. (b) THBS1 expression was reactivated in RKO, CEM and RAJI using the methylation inhibitor 5-deoxy-azacytidine (left panel, 7 are controls, + refers to treated with 5-deoxy-azacytidine). This reactivation was accompanied by variable amounts of demethylation of the THBS1 promoter as determined by bisul®te/PCR (right panel). Per cent methylation (indicated below each lane) was determined by measuring the density of the methylation bands (at 101 and 86 bp, indicated by arrows) relative to the total density of all three bands in each lane Figure 4 Hypermethylation of the THBS1 promoter in primary GBM. (a) Shown are representative (composite) Southern blots of 24 primary GBM tumors. The ®rst lane (EcoRI¯ank) is a sample of normal colon DNA digested with EcoRI alone, while all other lanes (GBM tumors 1 ± 24) are digested with EcoRI and NotI. As in Figure 2a , the 0.9 kb band is independent of methylation status, while the 3.2 kb band indicates methylation of the NotI site in the THBS1 promoter. Note that GBM tumors 2, 3, 7, 8, 15, 17, 18 and 24 are partially or completely methylated (as indicated by the band at 3.2 kb and the arrow on the right). In this analysis, incomplete methylation usually re¯ects the fact that most primary tumors contain normal stroma and in®ltrating lymphocytes as well, but may also be due to true tumor heterogeneity. (b) Representative bisul®te/PCR analysis of primary GBM tumors. As in Figure 2c , methylated samples have bands at 101 and 86 bp (indicated by arrows). Lane 1 is undigested DNA, while all others (2 ± 20) are digested with BstUI. Lane 14 is a positive control (RKO). Seven of the 18 GBM samples shown here are the same as samples in (a). Thus, samples in lanes 7, 9, 11 ± 13, 15 and 16 of (a) are the same as samples in lanes 11, 20, 10, 9, 8, 12 and 13 of (b) (respectively). Note that the primary GBMs in lanes 2, 4, 11, 12, 17 and 18 are partially or completely methylated
Thrombospondin-1 promotor methylation in cancer Q Li et al methylation in a subset of colorectal tumors with microsatellite instability (Ahuja et al., 1997) , and speculated that this methylation could be due to mismatch repair de®ciency in those cells. In the present study, however, we demonstrate that THBS1 methylation is relatively frequent in GBM, a tumor type that very infrequently displays mismatch repair de®ciency. Indeed, none of the samples we studied have the extensive microsatellite instability associated with mismatch repair de®ciency (Burger et al., unpublished observations). Furthermore, we have previously shown a link between carcinogen exposure and hypermethylation involving the ER CpG island in lung tumors (Issa et al., 1996) , and suggested that some cancers may evolve along a`hypermethylator' pathway. However, there was no correlation between THBS1 and ER methylation in the current study, suggesting that THBS1 methylation is not simply a marker for this hypermethylator pathway. A possible explanation for our results, then, is that THBS1 methylation is a rare event during cellular replication that confers aected cells with a selective growth advantage. In this respect, THBS1 methylation may therefore arise through mechanisms similar to tumor suppressor gene methylation in cancer , including Rb, VHL, and P16.
To our knowledge, this is the ®rst report of inactivation of an angiogenesis inhibitor gene in association with promoter methylation. Despite intense interest in the ®eld, there have been few speci®c molecular defects described in genes regulating neovascularization. Our data now suggests that promoter methylation should be investigated as a potential mechanism for regulating this process. Furthermore, since neovascularization is an early event in many tumors, these studies raise the possibility of using methylation inhibitors in patients diagnosed with early stages of neoplasia, in the hope of preventing dissemination and/or recurrence after initial therapy. In this respect, GBM may serve as a useful model to test this hypothesis.
Materials and methods
Tissue samples
Primary colonic tissue and GBM samples were obtained at surgical resection, and control brain tissue was provided by the Brain Resource Center of the Johns Hopkins University Alzheimer's Disease Research Center. The collection of these tissue samples were approved by the Joint Committee on Clinical Investigation of the Johns Hopkins Hospital in accordance with the policies of the Department of Health and Human Services.
Cell culture
All cell lines were obtained from the American Type Culture Collection except RKO which was kindly provided by Dr Bert Vogelstein. The leukemia cell lines CEM, RAJI and ML1 were maintained in RPMI 1640 supplemented with 10% fetal bovine serum. All other cell lines were maintained in DMEM with 10% fetal bovine serum. All cell culture reagents were purchased from Paragon Biotech (Baltimore, MD, USA). For the demethylation experiments, cells were treated with 5-deoxy-azacytidine (Sigma) at 1 mM concentration for 2 ± 5 days.
Southern analysis
Genomic DNA was prepared from primary tissues or cultured cells using standard methods. For analysis of THBS1 gene methylation status, 5 mg of genomic DNA were digested with 50 units of EcoRI and 100 units of a methylation sensitive enzyme (NotI, EagI or SacII) as recommended by the manufacturer (all restriction enzymes were purchased from New England Biolabs, MA, USA). DNA fragments were then separated in a 1% agarose gel, transferred to a nylon membrane (BioRad) and hybridized with the appropriate probe for 12 ± 16 h. All probes were 32 PdCTP labeled using a random priming kit (Boehringer). The blots were then washed, exposed in a phosphor screen (Molecular Dynamics) for 2 ± 4 days, imaged in a phosphorimager (Molecular Dynamics) and analysed with the ImageQuant software (Molecular Dynamics).
Two THBS1 probes were used for analysis of methylation (see Figure 1) ; The ®rst probe, THBS1-12 (3' to the CpG island) was obtained by digesting plasmid pts33 (ATCC) with StyI and gel-purifying the 400 bp fragment. The second probe, THBS1-34 containing 611 bp of promoter sequence 885 bp upstream from the transcription start site was generated by PCR ampli®cation of genomic DNA using the following primers: Upper primer, ATACAACACTCC-CACGCAAGAAA; lower primer, TATCCAGTTTCCA-CAAGCCAA. To ensure complete digestion by the restriction enzymes, all blots were stripped and reprobed with a control probe (ABL1).
Bisul®te-PCR analysis
Bisul®te treatment of DNA was performed as described (Herman et al., 1996) . Primers GGAGAGAGGAGTTTA-GATTGGTT (upper panel) and AATAAAAATTACTCC-TAAAAAAC (lower) were used to amplify a 187 bp fragment surrounding the transcription start site of the THBS1 gene. Methylation was determined by digestion of the PCR product with the restriction enzymes BstUI, TaqI or BsmI, all of which will only digest DNA if the CG site(s) in their recognition sequence was methylated prior to bisul®te treatment, and thus was not converted to TG.
RT ± PCR
Total RNA was prepared using standard methods. Six mg of total RNA were used to generate cDNA using random hexamers and M-MuLV reverse transcriptase enzyme, as recommended by the manufacturer (Boehringer Mannheim). About one tenth of the cDNA was used as a template to amplify a 550 bp fragment speci®c to the THBS1 transcript. Another one thirtieth of cDNA product was used to amplify a 306 bp fragment speci®c to the GAPDH gene transcript as a control for RNA integrity. The primers used are: CCAGCTGTACATCGACTGTGA (upper) and GCAGA-TGGTAACTGAGTTCTGA (lower) for THBS1; CGGAGT-CAACGGATTTGGTCGTAT (upper) and AGCCTTCTC-CATGGTGGTGAAGAC (lower) for GAPDH. All RT ± PCR reactions included negative controls were the RT enzyme was omitted.
